Following the pre-NDA meeting, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD The planned initial submission package will be for the treatment of MDD with an anticipated PPD filing thereafter

Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, 2021 at 8:00am ET CAMBRIDGE,

Effort embodies Sage’s long-term commitment to investing in People, Patients, Planet and Community CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2021-- Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 21, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 15, 2021-- Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S.

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 4, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present

Announced positive topline data from pivotal WATERFALL Study of zuranolone in patients with MDD showing statistically significant and clinically meaningful reduction in depressive symptoms at Day 15, primary endpoint Continued pipeline expansion and acceleration advancing all three brain health

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will